Draft:Genfit

Genfit is a French biotechnology company. It's research and clinical trials in the fields of cardiovascular disease and liver disease, especially of metabolic origin. Genfit is also involved in the development of medical diagnostic technology.

It has been listed on the Euronext Paris stock exchange since 2006 and on the NASDAQ since 2019.

History and Activity
Genfit was founded in 1999 in Lille by Jean-François Mouney and Florence Séjourné with the support of professors Bart Staels and Jean-Charles Fruchart. The company initially focused on the development of drugs for cardiovascular diseases and obesity. In 2006, Genfit went public on Alternext, raising €15 million. In 2014, the company's stock was included in the SBF 120 index. However, it was removed from the index in 2020.

In 2016, Genfit raised €44.6 million in a capital increase. In 2017, the company issued €180 million of convertible bonds (OCEANE) to institutional investors. Half of the amount of these bonds was cancelled in January 2021 and the balance carried forward to the end of 2025.

In March 2019, Genfit also listed on the Nasdaq, raising $135.1 million. In September 2019, CEO Jean-François Mouney became Chairman of the Board of Directors and Pascal Prigent became CEO.

In May 2020, Genfit discontinued its "investigations into the treatment of non-alcoholic steatohepatitis (NASH)". As of late September 2020, the company is focusing on "primary biliary cholangitis (PBC) and NIS4, a blood diagnostic technology that, if approved, would identify patients at risk of NASH".